Creative Biolabs provides the high specific and affinity native guinea pig monoclonal antibody generation service by our propriety Native™ Antibody Discovery Platform.
Guinea pig (Cavia porcellus), which is suggested as domesticated descendants of a closely related species of cavy, is a kind of rodent that do not exist naturally in the wild. Guinea pigs have been treated as experimental animals for various scientific researches since 17th century. In the period of more than 200 years, guinea pigs were widely applied in the standardization of vaccines and antiviral agents, the research and diagnosis of infectious diseases and the production of antibodies against extreme allergic reactions or anaphylaxis. This popularity, therefore, makes “guinea pig” a metaphor for a subject of scientific experimentation, or any experiment or test in modern times. While the currently used mice and rats have replaced the position of guinea pigs in laboratory contexts to a great extent, the species are still frequently used to diagnose tuberculosis through the infection of human tuberculosis bacteria.
According to the progress of guinea pigs related research, this species has become a de novo source for the generation of antigen-specific monoclonal antibodies. Compared with other small experimental animals, guinea pigs indicate remarkable physiological similarities with humans and higher sensibility to induce immune response for some targets, which are hardly recognized by other rodents. For instance, due to the unusual insulin mutation, guinea pigs are ideal species for the generation of high affinity antibodies against human insulin. Therefore, monoclonal antibody of guinea pig may play a potential role in the research and development of therapeutic antibody.
Beside producing monoclonal guinea pig antibody through phage display technology or hybridoma technology, Creative Biolabs offers an alternative choice to develop native guinea pig monoclonal antibody by our powerful Native™ Antibody Discovery Platform. This platform, which is combined with the antigen-specific B lymphocytes cytometry technology, is able to obtain target-specific guinea pig monoclonal antibodies paired with native heavy- and light-chains. In addition, this platform also enables the isolation of large amount of candidate antibodies that go through in vivo affinity maturation. Accordingly, the final produced native guinea pig monoclonal antibodies will possess extremely high specificity and affinity.
Creative Biolabs has years of experience in the antibody generation, and has supplied thousands of different antibodies for our global customers. Our experienced scientists are confident in providing the best service and generating the high quality native guinea pig monoclonal antibody to facilitate our customers’ research and project development.